Inventiva (NASDAQ:IVA) Stock Price Down 6.3% – Should You Sell?

Inventiva S.A. Sponsored ADR (NASDAQ:IVA)’s share price dropped 6.3% during trading on Thursday . The stock traded as low as $4.79 and last traded at $4.7810. Approximately 80,131 shares traded hands during mid-day trading, a decline of 81% from the average daily volume of 431,862 shares. The stock had previously closed at $5.10.

Analyst Ratings Changes

IVA has been the subject of several research analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Inventiva in a research note on Wednesday, October 8th. UBS Group assumed coverage on shares of Inventiva in a research report on Wednesday. They issued a “buy” rating and a $12.00 price target for the company. HC Wainwright boosted their price objective on shares of Inventiva from $20.00 to $24.00 and gave the company a “buy” rating in a research report on Thursday, October 9th. Canaccord Genuity Group reiterated a “buy” rating and issued a $20.00 price objective on shares of Inventiva in a research note on Tuesday, September 30th. Finally, Wall Street Zen raised shares of Inventiva to a “hold” rating in a research note on Saturday, October 18th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Inventiva currently has an average rating of “Moderate Buy” and a consensus price target of $16.57.

Inventiva Price Performance

The business has a 50 day moving average price of $4.32 and a 200 day moving average price of $4.46.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in IVA. NewEdge Advisors LLC bought a new stake in Inventiva in the third quarter valued at $116,000. Millennium Management LLC acquired a new stake in shares of Inventiva during the 3rd quarter worth about $649,000. Wealth Enhancement Advisory Services LLC lifted its holdings in Inventiva by 55.6% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 25,770 shares of the company’s stock valued at $142,000 after purchasing an additional 9,212 shares during the last quarter. Finally, Creative Planning acquired a new position in Inventiva in the second quarter valued at about $32,000. Institutional investors and hedge funds own 19.06% of the company’s stock.

Inventiva Company Profile

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.